Skip to main content
. Author manuscript; available in PMC: 2021 Nov 1.
Published in final edited form as: Mol Cancer Ther. 2021 Feb 25;20(5):816–832. doi: 10.1158/1535-7163.MCT-20-0354

Figure 3. IMD-0354 Treatment Inhibits Glutamine Uptake and Suppresses Associated Amino Acid Biosynthesis.

Figure 3.

(a) A431 cells were treated with vehicle, IMD-0354 (5 μM or 10 μM) for 1h or 24h followed by 3H-glutamine uptake assay. (b) A431 and A375 cells were treated with increasing concentrations of IMD-0354 for 1h followed by 3H-glutamine uptake assay. (c) A431 cells were treated with 2 μM of IMD-0354 for 72h, intracellular glutamine and glutamate levels were determined by GC-MS. (d) A431 cells were treated with 2 μM of IMD-0354 for 72h, glutamine level in media was determined by GC-MS. (e, f) A431 cells were treated with the indicated concentrations of IMD-0354 for 6h followed by GC-MS-based analysis. Statistical analysis was performed by one-way ANOVA for the comparison of more than two groups. Unpaired t-test was used for the comparison of two groups. Data are shown as the mean ± SD, n = 3. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001.